Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on February 23, 2023. The filing primarily addresses modifications to executive compensation arrangements effective January 1, 2023, and the formal establishment of a Board Science Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments and corporate governance updates.
Material Changes
Executive Compensation Modifications
The Compensation Committee and Board approved annual base salary increases and equity awards for six executive officers, effective January 1, 2023. The changes are detailed below:
| Executive Officer | Role | Base Salary Increase | 2022 Bonus Awarded | Equity Grants (Options/RSUs/PSUs) |
|---|---|---|---|---|
| Jack A. Khattar | President & CEO | $913,500 to $963,000 | $685,125 | 280,000 Options, 140,000 PSUs |
| Timothy C. Dec | SVP & CFO | $412,500 to $453,800 | $178,200 | 40,000 Options, 10,000 RSUs, 10,000 PSUs |
| Padmanabh P. Bhatt, Ph.D. | SVP, IP & CSO | $415,200 to $427,700 | $140,973 | 20,000 Options, 5,000 RSUs, 5,000 PSUs |
| Jonathan Rubin, M.D. | SVP & CMO | $412,000 to $440,000 | $149,291 | 20,000 Options, 5,000 RSUs, 7,500 PSUs |
| Tami T. Martin, R.N., Esq. | SVP, Regulatory Affairs | $346,300 to $356,700 | $109,080 | 20,000 Options, 5,000 RSUs, 5,000 PSUs |
| Frank Mottola | SVP, Quality, GMP & IT | $342,400 to $352,700 | $116,246 | 30,000 Options, 7,500 RSUs, 7,500 PSUs |
Equity Terms: Stock options have an exercise price of $38.60 per share. Options and RSUs vest annually in equal increments over four years. PSUs vest based on the achievement of specified performance goals.
Formation of Science Committee
The Board formalized a Science Committee to engage in focused discussions on research and development programs. The committee members are Carrolee Barlow (Chair), Georges Gemayel, and John Siebert.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. The compensation increases were benchmarked against an industry peer group by the independent consultant Radford.
Investor Verification Checklist
- Verify the total dilution impact of the new equity grants (options, RSUs, and PSUs) on outstanding share counts.
- Review the specific performance goals attached to the Performance Share Units (PSUs) to understand vesting conditions.
- Confirm the company's cash burn rate and liquidity position in the most recent 10-Q or 10-K to assess the sustainability of increased fixed compensation costs.
- Monitor future filings for the actual vesting of PSUs based on the achievement of the stated performance goals.